spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DEBIOPHARM GROUP 

 HSMN NewsFeed - 16 May 2019
GenePOC Obtains FDA Clearance for its GenePOC(TM) Carba Test in the US
Diagnostics FDA
 HSMN NewsFeed - 19 Feb 2018
GenePOC Launches Its revogene(TM) Instrument and GBS LB Test in Canada
Diagnostics Product Launch
 HSMN NewsFeed - 28 Nov 2017
GenePOC Launches its GenePOC(TM) CDiff Test in the United States
Diagnostics FDA Product Launch
 HSMN NewsFeed - 30 Jun 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2017
GenePOC Announces FDA Clearance for Revogene(TM) Instrument and its GBS LB Test
Diagnostics FDA
 HSMN NewsFeed - 2 Jun 2016
FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Mar 2016
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
Biopharmaceuticals Generics Oncology Litigation
 HSMN NewsFeed - 19 May 2015
Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)
Biopharmaceuticals
 HSMN NewsFeed - 12 Jan 2015
Debiopharm Group(TM) Regains Full Rights to Alisporivir Program
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2014
Orient EuroPharma and Debiopharm Group(TM) Announce Their Partnership and the Launch of Pamorelin(R) LA in Singapore
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2014
Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group(TM)
Diagnostics Venture Capital
 HSMN NewsFeed - 9 Jan 2013
Spinomix Closes a $ 3 Million Financing Round Led by Debiopharm Group
Diagnostics Venture Capital
 HSMN NewsFeed - 7 Dec 2012
Dr. Reddy's Launches Debiopharm's Pamorelin(R) LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2012
Debiopharm Group(TM) - First Patient Treated in Phase III Study With Subcutaneous Administration of Debio 8206 for Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2012
Debiopharm and Ascepion Pharmaceuticals, Inc. Announce Exclusive License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jan 2011
Diagnoplex Closes an Extension of its Series A Financing With a Substantial Investment by Debiopharm Group(TM)
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 9 Feb 2010
Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Feb 2010
Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2010
Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2009
Ipsen's Decapeptyl(R) 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jul 2009
Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jul 2009
Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
Biopharmaceuticals Urology Oncology FDA
 HSMN NewsFeed - 23 Jun 2009
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2009
Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 4 Nov 2008
Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding - Debiopharm Submits Response to the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2008
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 15 May 2008
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Feb 2008
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2006
Debiopharm Signs International License Agreements for Sanvar(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Jul 2006
Debiopharm Applies for First European Marketing Authorisation for Sanvar(R) in France
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jun 2006
The Debiopharm Group to initiate confirmatory Phase III trial for Sanvar(R) in esophageal variceal bleeding
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.